Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain

Seasoned RNAi and CNS leaders come together to build a pipeline of systemically administered RNA medicines using advances in ...
Agence France-Presse

Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

“Bi-specific ADCs hold significant promise as the next generation of cancer therapies,” mentioned Bertrand Ducrey, CEO of Debiopharm. “We’re excited to confirm this licensing option as it allows us to ...

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of ...

enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of ...
Santé log

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish ...
Santé log

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and ...

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer ...

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in ...